Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis

Giovanni Ponti, Monia Maccaferri, Marco Manfredini, Salvatore Micali, Federica Torricelli, Riccardo Milandri, Chiara del Prete, Alessia Ciarrocchi, Cristel Ruini, Luisa Benassi, Stefania Bettelli, Shaniko Kaleci, Tomris Ozben, Aldo Tomasi

Research output: Contribution to journalArticle

Abstract

Background: Liquid biopsy consists in the quantification and qualification of circulating cell-free DNA (cfDNA) and tumor-derived DNA (ctDNA) for cancer recognition. Recently, the characterization of seminal cfDNA (scfDNA) has been reported as a possible biomarker for prostate cancer (PCa) diagnosis. Methods: Thirty patients with histologically proven PCa, 33 with benign prostate hyperplasia (BPH) and 21 healthy controls were enrolled. cfDNA was extracted from seminal fluid samples. cfDNA quantification and analysis were performed using Qubit ssDNA Kit and Agilent 2100 Bioanalyzer. Statistical analysis included: Levene's test, Shapiro-Wilk, Kolmogorov-Smirnov and Kruskal Wallis tests. Results: Median cfDNA was significantly higher in PCa patients 428.45 ng/mL (173.93–1159.62) compared to BPH patients 77.4 ng/mL (18.23–501) and healthy controls 25.4 ng/mL (15.37–76.62). scfDNA fragments longer than 1000 base-pairs were more common in patients with PCa compared to those with BPH and controls. Conclusions: scfDNA concentration and fragment size differed significantly in the three groups of PCa, BPH and healthy controls. Both parameters are potential clinical biomarkers for PCa and can be used in both early diagnosis and follow-up. Using automated systems for high-throughput cfDNA quantification could improve the reproducibility of the method and facilitate the implementation of liquid biopsies in the clinical setting.

Original languageEnglish
Pages (from-to)76-80
Number of pages5
JournalClinica Chimica Acta
Volume497
DOIs
Publication statusPublished - Oct 1 2019

Fingerprint

Prostatic Neoplasms
Fluids
DNA
Hyperplasia
Prostate
Biopsy
Biomarkers
Liquids
Base Pairing
Tumors
Early Diagnosis
Neoplasms
Statistical methods
Throughput

Keywords

  • Benign prostatic hyperplasia
  • cfDNA fragment size distribution
  • Non-invasive prostate cancer diagnosis
  • Seminal cell-free DNA

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Ponti, G., Maccaferri, M., Manfredini, M., Micali, S., Torricelli, F., Milandri, R., ... Tomasi, A. (2019). Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis. Clinica Chimica Acta, 497, 76-80. https://doi.org/10.1016/j.cca.2019.07.011

Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis. / Ponti, Giovanni; Maccaferri, Monia; Manfredini, Marco; Micali, Salvatore; Torricelli, Federica; Milandri, Riccardo; del Prete, Chiara; Ciarrocchi, Alessia; Ruini, Cristel; Benassi, Luisa; Bettelli, Stefania; Kaleci, Shaniko; Ozben, Tomris; Tomasi, Aldo.

In: Clinica Chimica Acta, Vol. 497, 01.10.2019, p. 76-80.

Research output: Contribution to journalArticle

Ponti, G, Maccaferri, M, Manfredini, M, Micali, S, Torricelli, F, Milandri, R, del Prete, C, Ciarrocchi, A, Ruini, C, Benassi, L, Bettelli, S, Kaleci, S, Ozben, T & Tomasi, A 2019, 'Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis', Clinica Chimica Acta, vol. 497, pp. 76-80. https://doi.org/10.1016/j.cca.2019.07.011
Ponti, Giovanni ; Maccaferri, Monia ; Manfredini, Marco ; Micali, Salvatore ; Torricelli, Federica ; Milandri, Riccardo ; del Prete, Chiara ; Ciarrocchi, Alessia ; Ruini, Cristel ; Benassi, Luisa ; Bettelli, Stefania ; Kaleci, Shaniko ; Ozben, Tomris ; Tomasi, Aldo. / Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis. In: Clinica Chimica Acta. 2019 ; Vol. 497. pp. 76-80.
@article{f820aefc428645d481c85b3e118a0663,
title = "Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis",
abstract = "Background: Liquid biopsy consists in the quantification and qualification of circulating cell-free DNA (cfDNA) and tumor-derived DNA (ctDNA) for cancer recognition. Recently, the characterization of seminal cfDNA (scfDNA) has been reported as a possible biomarker for prostate cancer (PCa) diagnosis. Methods: Thirty patients with histologically proven PCa, 33 with benign prostate hyperplasia (BPH) and 21 healthy controls were enrolled. cfDNA was extracted from seminal fluid samples. cfDNA quantification and analysis were performed using Qubit ssDNA Kit and Agilent 2100 Bioanalyzer. Statistical analysis included: Levene's test, Shapiro-Wilk, Kolmogorov-Smirnov and Kruskal Wallis tests. Results: Median cfDNA was significantly higher in PCa patients 428.45 ng/mL (173.93–1159.62) compared to BPH patients 77.4 ng/mL (18.23–501) and healthy controls 25.4 ng/mL (15.37–76.62). scfDNA fragments longer than 1000 base-pairs were more common in patients with PCa compared to those with BPH and controls. Conclusions: scfDNA concentration and fragment size differed significantly in the three groups of PCa, BPH and healthy controls. Both parameters are potential clinical biomarkers for PCa and can be used in both early diagnosis and follow-up. Using automated systems for high-throughput cfDNA quantification could improve the reproducibility of the method and facilitate the implementation of liquid biopsies in the clinical setting.",
keywords = "Benign prostatic hyperplasia, cfDNA fragment size distribution, Non-invasive prostate cancer diagnosis, Seminal cell-free DNA",
author = "Giovanni Ponti and Monia Maccaferri and Marco Manfredini and Salvatore Micali and Federica Torricelli and Riccardo Milandri and {del Prete}, Chiara and Alessia Ciarrocchi and Cristel Ruini and Luisa Benassi and Stefania Bettelli and Shaniko Kaleci and Tomris Ozben and Aldo Tomasi",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.cca.2019.07.011",
language = "English",
volume = "497",
pages = "76--80",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis

AU - Ponti, Giovanni

AU - Maccaferri, Monia

AU - Manfredini, Marco

AU - Micali, Salvatore

AU - Torricelli, Federica

AU - Milandri, Riccardo

AU - del Prete, Chiara

AU - Ciarrocchi, Alessia

AU - Ruini, Cristel

AU - Benassi, Luisa

AU - Bettelli, Stefania

AU - Kaleci, Shaniko

AU - Ozben, Tomris

AU - Tomasi, Aldo

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Background: Liquid biopsy consists in the quantification and qualification of circulating cell-free DNA (cfDNA) and tumor-derived DNA (ctDNA) for cancer recognition. Recently, the characterization of seminal cfDNA (scfDNA) has been reported as a possible biomarker for prostate cancer (PCa) diagnosis. Methods: Thirty patients with histologically proven PCa, 33 with benign prostate hyperplasia (BPH) and 21 healthy controls were enrolled. cfDNA was extracted from seminal fluid samples. cfDNA quantification and analysis were performed using Qubit ssDNA Kit and Agilent 2100 Bioanalyzer. Statistical analysis included: Levene's test, Shapiro-Wilk, Kolmogorov-Smirnov and Kruskal Wallis tests. Results: Median cfDNA was significantly higher in PCa patients 428.45 ng/mL (173.93–1159.62) compared to BPH patients 77.4 ng/mL (18.23–501) and healthy controls 25.4 ng/mL (15.37–76.62). scfDNA fragments longer than 1000 base-pairs were more common in patients with PCa compared to those with BPH and controls. Conclusions: scfDNA concentration and fragment size differed significantly in the three groups of PCa, BPH and healthy controls. Both parameters are potential clinical biomarkers for PCa and can be used in both early diagnosis and follow-up. Using automated systems for high-throughput cfDNA quantification could improve the reproducibility of the method and facilitate the implementation of liquid biopsies in the clinical setting.

AB - Background: Liquid biopsy consists in the quantification and qualification of circulating cell-free DNA (cfDNA) and tumor-derived DNA (ctDNA) for cancer recognition. Recently, the characterization of seminal cfDNA (scfDNA) has been reported as a possible biomarker for prostate cancer (PCa) diagnosis. Methods: Thirty patients with histologically proven PCa, 33 with benign prostate hyperplasia (BPH) and 21 healthy controls were enrolled. cfDNA was extracted from seminal fluid samples. cfDNA quantification and analysis were performed using Qubit ssDNA Kit and Agilent 2100 Bioanalyzer. Statistical analysis included: Levene's test, Shapiro-Wilk, Kolmogorov-Smirnov and Kruskal Wallis tests. Results: Median cfDNA was significantly higher in PCa patients 428.45 ng/mL (173.93–1159.62) compared to BPH patients 77.4 ng/mL (18.23–501) and healthy controls 25.4 ng/mL (15.37–76.62). scfDNA fragments longer than 1000 base-pairs were more common in patients with PCa compared to those with BPH and controls. Conclusions: scfDNA concentration and fragment size differed significantly in the three groups of PCa, BPH and healthy controls. Both parameters are potential clinical biomarkers for PCa and can be used in both early diagnosis and follow-up. Using automated systems for high-throughput cfDNA quantification could improve the reproducibility of the method and facilitate the implementation of liquid biopsies in the clinical setting.

KW - Benign prostatic hyperplasia

KW - cfDNA fragment size distribution

KW - Non-invasive prostate cancer diagnosis

KW - Seminal cell-free DNA

UR - http://www.scopus.com/inward/record.url?scp=85069664900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069664900&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2019.07.011

DO - 10.1016/j.cca.2019.07.011

M3 - Article

AN - SCOPUS:85069664900

VL - 497

SP - 76

EP - 80

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -